These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15583696)

  • 1. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.
    Memon AA; Sorensen BS; Melgard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2004 Dec; 91(12):2034-41. PubMed ID: 15583696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
    Memon AA; Sorensen SB; Nexo E
    Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
    Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
    Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer.
    Nielsen TO; Borre M; Nexo E; Sorensen BS
    BJU Int; 2015 Jan; 115(1):163-5. PubMed ID: 24467768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
    Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
    Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
    Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
    BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
    Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
    Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
    Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
    Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.
    Nielsen TO; Friis-Hansen L; Poulsen SS; Federspiel B; Sorensen BS
    PLoS One; 2014; 9(4):e94606. PubMed ID: 24728052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
    Lipponen P; Eskelinen M
    Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
    Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
    Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
    Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
    Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
    Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
    Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.